I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

CTAD 2023

-
Coming soon
12:00 PM
Duration 96hrs Boston, USA
Alzheimer's disease linkage to evidence (AD-LINE) study: An analysis of concordance between clinical diagnosis and evidence of AD diagnosis in real-world US claims data
Desilu Glazebrook

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:00 PM
Duration 96hrs Boston, USA
RG6289, a new γ-secretase modulator for the treatment of Alzheimer’s disease: Dose selection for a phase II trial based on population PK/PD modeling
Agnes Portron

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 96hrs Boston, USA
Baseline risk factors for ARIA-E in the GRADUATE I and II studies of gantenerumab
Paul Delmar

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 96hrs Boston, USA
Assessing health system capacity for delivery of a disease-modifying therapy for Alzheimer’s disease: a multi-country analysis
Nathalie Budd

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:35 PM
Duration 10mins Boston, USA
THE ANTI-AMYLOID BETA “BRAIN SHUTTLE” ANTIBODY TRONTINEMAB RAPIDLY REDUCES AMYLOID PLAQUES IN PARTICIPANTS WITH ALZHEIMER’S DISEASE
Luka Kulic

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:00 PM
Duration 96hrs Boston, USA
Pharmacodynamic Effects of Semorinemab on Biomarkers of Tau, Synaptic Function, and Gliosis in a Phase 2 Trial of Mild-to-Moderate Alzheimer’s Disease
Stephen Schauer

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 96hrs Boston, USA
Measuring changes in longitudinal Tau-PET with [18F]MK-6240: group-level vs individualized ROIs definition
Nick Sidorenko

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:00 PM
Duration 10mins Boston, USA
An exploration of amyloid removal measures in relation to clinical benefit: a review and meta-regression of anti-amyloid trials in AD.
Marzia A. Scelsi (lead author) / Paul Delmar (presenter)

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:00 PM
Duration 96hrs Boston, USA
Automated linguistic metrics from a novel, remote, smartphone-based self-assessment of cued narration and free recall correlate with brain atrophy in language and memory networks in early Alzheimer’s disease
Irma Kurniawan

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar